Table 4.
Coronary Events After 1‐Year with Adjustment for Baseline Factors, Baseline Biomarkers and Change in Biomarkers
| Variables | Level | HR (95% CI) | P Value Trend |
|---|---|---|---|
| Baseline Lp‐PLA2 activity | ≤229.142 | 1 | 0.04 |
| 229.142 to 261.028 | 1.14 (0.91, 1.42) | ||
| 261.028 to 293.767 | 1.11 (0.89, 1.39) | ||
| >293.767 | 1.27 (1.01, 1.58) | ||
| Change in Lp‐PLA2 activity | ≤−46.6057 | 1 | <0.001 |
| −46.6057 to −19.8282 | 1.16 (0.92, 1.47) | ||
| −19.8282 to 2.8565 | 1.29 (0.99, 1.69) | ||
| >2.8565 | 1.61 (1.23, 2.11) |
Lp‐PLA2 indicates lipoprotein‐associated phospholipase A2; HR, hazard ratio.
Baseline Factors: Treatment, sex, stroke, diabetes, smoking, hypertension, total cholesterol, apolipoprotein B and A1, HDL cholesterol, age, nature of prior acute coronary syndromes, timing of coronary revascularization, systolic blood pressure, atrial fibrillation, estimated glomerular filtration rate, body mass index, dyspnea class, angina grade, white blood cell count, peripheral vascular disease, triglycerides, fasting glucose, and aspirin at baseline.
Baseline Biomarkers: Baseline brain natriuretic peptide, baseline cystatin C, baseline D‐dimer, baseline troponin I, and baseline Lp‐PLA2.
Change in Biomarkers: Change in brain natriuretic peptide, troponin I, and Lp‐PLA2 activity.